Note dell’episodio
In this episode, Will Tjernlund speaks with Dr. Bill Williams, President and CEO of BriaCell Therapeutics, a clinical-stage immuno-oncology company trading under the ticker BCTX.
Dr. Williams discusses his transition from academia to the biotechnology industry, his role in advancing the blockbuster drug Jakafi, and why he personally invested millions of dollars in BriaCell alongside Chairman Jamieson Bondarenko.
The conversation explores BriaCell’s lead candidate, Bria-IMT, an investigational immunotherapy being evaluated in late-stage metastatic breast cancer patients who have exhausted…

